CLOs on the Move


 
DMC is leading the low cost sustainable transformation of multiple product markets.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.dmcbio.com
  • 2477 55th St, Suite 120
    Boulder, CO USA 80303
  • Phone: N/A

Executives

Name Title Contact Details

Similar Companies

Mantra Bio

Mantra Bio is harnessing exosomes to deliver safe, highly targeted medicines. We are the creator of REVEAL™, an exosome engineering platform combining computational biology and lab automation to generate targeted exosome vehicles (TEVs) for a broad set of therapeutic areas.

Puerto Rico Labor and Human Resources

Puerto Rico Labor and Human Resources is a New York, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

T-knife

T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a modality that holds the potential to generate transformative responses in patients with solid tumors. The Company`s unique approach leverages its proprietary HuTCR mouse platform, a next-generation T cell receptor and epitope discovery engine that produces fully human, tumor-specific TCRs, naturally selected in vivo for optimal affinity and high specificity. T-knife is advancing a portfolio of TCR-T product candidates against targets with high unmet medical need, including cancer testis antigens, oncoviral antigens and commonly shared tumor-driving neoantigens. T-knife was founded by leading T-cell and immunology experts using technology developed at the Max Delbruck Center for Molecular Medicine together with Charité – Universitätsmedizin Berlin.

Precision Health Media

New York-based Precision Health Media (formerly Good Health Media) delivers specific health condition audiences to pharma and consumer brands.

Exosome Diagnostics

Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company`s proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.